The efficacy of MEK inhibitors has previously been shown in NF1-deficient glioblastoma cell lines (52), in addition to clinical benefit in refractory neurofibromatosis-associated glioma harboring the NF1 mutation (53–55). The gene discussed is MAP2K7; the disease is central nervous system cancer.